z-logo
open-access-imgOpen Access
Subcutaneous Implantable Cardioverter‐Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Transatlantic Experience
Author(s) -
Orgeron Gabriela M.,
Bhonsale Aditya,
Migliore Federico,
James Cynthia A.,
Tichnell Crystal,
Murray Brittney,
Bertaglia Emanuele,
CadrinTourigny Julia,
De Franceschi Pietro,
Crosson Jane,
Tandri Harikrishna,
Corrado Domenico,
Calkins Hugh
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.118.008782
Subject(s) - medicine , implantable cardioverter defibrillator , arrhythmogenic right ventricular dysplasia , cardiology , interquartile range , cardiac resynchronization therapy , ventricular fibrillation , sudden cardiac death , cardiomyopathy , dysplasia , cohort , implant , surgery , heart failure , ejection fraction
Background Despite growing use of the subcutaneous implantable cardioverter‐defibrillator (S‐ ICD ), its clinical role in arrhythmogenic right ventricular cardiomyopathy/dysplasia ( ARVC /D) patients remains undefined. We aim to elucidate the cardiac phenotype, implant characteristics, and long‐term efficacy regarding appropriate therapy and complications in ARVC /D patients with an S‐ ICD implant. Methods and Results A transatlantic cohort of ARVC /D patients who underwent S‐ ICD implantation was analyzed for clinical characteristics, S‐ ICD therapy, and long‐term outcome including device‐related complications. The cohort included 29 patients (52% male, 76% probands, 59% with ARVC /D‐associated mutation, 59% primary prevention [no prior sustained ventricular arrhythmias], and 45% first‐generation S‐ ICD devices). At implant, all inducible patients (27/29) had conversion of induced ventricular fibrillation. Two patients (7%) had superficial infections of the incision site that were treated conservatively. Over a median follow‐up of 3.16 years (interquartile range: 2.21–4.51 years), all episodes (6 patients, 4% per year) of sustained ventricular arrhythmias were appropriately detected and treated. Six patients (21%) experienced 39 inappropriate shocks, with 3 requiring device explantation. Oversensing of noncardiac signal (n=4; especially myopotentials) and cardiac signal (n=4) was the most frequent etiology. No lead or device dislodgement, infection, skin erosion, or explantation related to need for antitachycardia pacing was noted. Conclusions S‐ ICD can effectively treat both induced and spontaneous ventricular arrhythmias in patients with ARVC /D. The rate of inappropriate shocks, although considerable, is comparable to that in ARVC /D patients treated with transvenous ICD s. When they occurred, inappropriate shocks were primarily due to cardiac and, uniquely, noncardiac oversensing. We suggest potential strategies for minimizing inappropriate therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here